Related references
Note: Only part of the references are listed.Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors
Kaitlynne N. Cunningham et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
Chisa Nakashima et al.
ALLERGOLOGY INTERNATIONAL (2022)
Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice
Hongbin Song et al.
DERMATOLOGIC THERAPY (2022)
An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Maddison Lensing et al.
FRONTIERS IN IMMUNOLOGY (2022)
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
Ulrich Mrowietz et al.
DERMATOLOGY AND THERAPY (2021)
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments
Magdalena Misiak-Galazka et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Long-lasting allergic patch test reactions to dental metal allergens in a patient with palmoplantar pustulosis and pustulotic arthro-osteitis
Maiko Kato et al.
JOURNAL OF DERMATOLOGY (2020)
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley B. Cohen et al.
RMD OPEN (2020)
JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
Krzysztof Szalus et al.
MICROORGANISMS (2020)
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani et al.
FRONTIERS IN IMMUNOLOGY (2019)
Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study
J. M. Bae et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
F. Valenzuela et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal
Michiyoshi Kouno et al.
JOURNAL OF DERMATOLOGY (2017)
Psoriasis and palmoplantar pustulosis: an endless debate?
A. M. G. Brunasso et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity?
M. Misiak-Galazka et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients
H. Trattner et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Insulin resistance, diabetes mellitus and thyroid dysfunction in patients with palmoplantar pustulosis: a case-controlled study
Hatice Atas et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2017)
Treatment of Alopecia Areata With Tofacitinib
Omer Ibrahim et al.
JAMA DERMATOLOGY (2017)
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
Isabelle M. Sanchez et al.
DERMATOLOGY AND THERAPY (2017)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Management of palmoplantar pustulosis: do we need to change?
U. Mrowietz et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Can we really separate palmoplantar pustulosis from psoriasis?
A. M. G. Brunasso et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
IL-8 as antibody therapeutic target in inflammatory diseases: Reduction of clinical activity in palmoplantar pustulosis
Lone Skov et al.
JOURNAL OF IMMUNOLOGY (2008)
Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP)
H Nozawa et al.
CLINICAL IMMUNOLOGY (2005)
Targeting the Jak/STAT pathway for immunosuppression
JJ O'Shea
ANNALS OF THE RHEUMATIC DISEASES (2004)